Mesoblast Launches Phase 3 Trial for Back Pain

Mesoblast Limited (AU:MSB) has released an update.

Mesoblast Limited has started patient enrollment for their Phase 3 trial of rexlemestrocel-L, a potential breakthrough treatment for chronic low back pain (CLBP) due to degenerative disc disease. The trial is supported by the FDA, which has granted the therapy RMAT designation, indicating the possibility of fast-tracked review processes. The company aims to provide a new solution for CLBP sufferers, potentially improving quality of life and reducing opioid dependency.

For further insights into AU:MSB stock, check out TipRanks’ Stock Analysis page.